Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

被引：0
|
作者：
Ninh M. La-Beck
Beth A. Zamboni
Alberto Gabizon
Hilary Schmeeda
Michael Amantea
Paola A. Gehrig
William C. Zamboni
机构：
[1] University of North Carolina at Chapel Hill,UNC Eshelman School of Pharmacy
[2] Texas Tech University Health Sciences Center,Center for Immunotherapeutic Research and Department of Pharmacy Practice, School of Pharmacy
[3] Carlow University,Department of Mathematics
[4] Shaare Zedek Medical Center and Hebrew University-School of Medicine,Department of Oncology
[5] Pfizer,Department of Clinical Pharmacology
[6] Inc.,Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UNC School of Medicine
[7] University of North Carolina at Chapel Hill,Molecular Therapeutics, Lineberger Comprehensive Cancer Center
[8] University of North Carolina at Chapel Hill,Institute for Pharmacogenomics and Individualized Therapy
[9] University of North Carolina at Chapel Hill,Carolina Center of Cancer Nanotechnology Excellence
[10] University of North Carolina at Chapel Hill,Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy
[11] University of North Carolina at Chapel Hill,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Doxil; Liposomal; Pharmacokinetics; Variability; Monocytes; Reticuloendothelial system; Doxorubicin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：43 / 50
页数：7
相关论文
共 50 条
  • [41] Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin
    Grenader, Tal
    Rosengarten, Ora
    Isacson, Rut
    Plotkin, Yevgeni
    Gabizon, Alberto
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2012, 3 (10): : 137 - 141
  • [42] Evaluating the effects of bortezomib (Velcade®) on the pharmacokinetics (PK) of pegylated liposomal doxorubicin (Doxil®, PLD)
    La-Beck, Ninh M.
    Walko, Christine M.
    Scoggins, Lakia
    Dees, E. Claire
    Orlowski, Robert Z.
    Wu, Huali
    Amantea, Michael
    Fardin, Mahsa
    Zamboni, William
    CANCER RESEARCH, 2012, 72
  • [43] A pegylated liposomal platform: Pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug
    Lu, WL
    Qi, XR
    Zhang, Q
    Li, RY
    Wang, GL
    Zhang, RJ
    Wei, SL
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 95 (03) : 381 - 389
  • [44] Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models
    Gabizon, A
    Tzemach, D
    Mak, L
    Bronstein, M
    Horowitz, AT
    JOURNAL OF DRUG TARGETING, 2002, 10 (07) : 539 - 548
  • [45] Clinical pharmacology of liposomal anthracyclines: Focus on pegylated liposomal doxorubicin
    Solomon, Rebecca
    Gabizon, Alberto A.
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01): : 21 - 32
  • [46] Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer
    Christodoulou, Christos
    Kostopoulos, Ioannis
    Kalofonos, Haralabos P.
    Lianos, Evangelos
    Bobos, Mattheos
    Briasoulis, Evangelos
    Gogas, Helen
    Razis, Evangelia
    Skarlos, Dimosthenis V.
    Fountzilas, George
    ONCOLOGY, 2009, 76 (04) : 275 - 285
  • [47] Pegylated liposomal doxorubicin is less cardiotoxic than conventional doxorubicin
    Reactions Weekly, 1998, 718 (1) : 6 - 6
  • [48] Pharmacokinetics of Pegylated Liposomal Doxorubicin Administered by Intraoperative Hyperthermic Intraperitoneal Chemotherapy to Patients with Advanced Ovarian Cancer and Peritoneal Carcinomatosis
    Salvatorelli, Emanuela
    De Tursi, Michele
    Menna, Pierantonio
    Carella, Consiglia
    Massari, Renato
    Colasante, Antonella
    Iacobelli, Stefano
    Minotti, Giorgio
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (12) : 2365 - 2373
  • [49] Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients
    Gorumlu, G.
    Kucukzeybek, Y.
    Kemal-Gul, M.
    Karaca, B.
    Cosan-Terek, M.
    Karabulut, B.
    Sanli, U. A.
    Akman, L.
    Ozsaran, A.
    Dikmen, Y.
    Uslu, R.
    JOURNAL OF BUON, 2008, 13 (03): : 349 - 352
  • [50] Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (CaelyxA®)
    Jung, S.
    Sehouli, J.
    Chekerov, R.
    Kluschke, F.
    Patzelt, A.
    Fuss, H.
    Knorr, F.
    Lademann, J.
    SUPPORTIVE CARE IN CANCER, 2017, 25 (11) : 3545 - 3549
12345